BMT Focus: Lymphoma
Linda Burns, M.D. is the medical director of the adult BMT unit at
University of Minnesota Medical Center, Fairview as well as a leader
in lymphoma research.
At the University of Minnesota Medical Center, Fairview Blood and Marrow Transplant (BMT) Program, your patients with lymphoma will experience our comprehensive approach, state-of-the-art research and novel treatment options which include both autologous and allogeneic transplantation as well as non-transplant trials.
We have extensive experience with the choices and applications of different stem cell sources. We also have conditioning regimen intensities tailored to the patients’ disease risk and tolerance for therapy. This allows us to provide specialized treatment options for patients with different types and stages of lymphoma.
Veronica Bachanova, M.D., Ph.D. provides exceptional research-based care for
patients at the University of Minnesota Medical Center, Fairview.
Our program has been at the forefront of BMT research and innovation for over 40 years providing the best care possible for patients with hematologic malignancies, marrow failure syndromes and metabolic disorders. We provide expert care for patients with lymphoma and offer treatment for patients in all phases of the disease including those with high risk and advanced disease.
Expert care combined with the latest clinical research
Providing superior care to every patient is our highest priority. We believe that patients deserve access to the latest scientific knowledge and advances in transplant research through participation in clinical trials. We offer trials specific to the University of Minnesota Medical Center, Fairview, as well as multicenter national trials. We currently have open research protocols for lymphoma patients including:
- Autologous transplant trials for chemotherapy-sensitive Hodgkin lymphoma and non-Hodgkin lymphoma patients including specialized trials for patients with HIV-associated lymphoma.
- Myeloablative and non-myeloablative allogeneic transplant trials are for advanced lymphoma using related-donor, unrelated-donor, or umbilical-cord-blood stem cells. Our extensive experience with all of these donor sources ensures that we can identify an allogeneic transplant donor and management strategy for every eligible lymphoma patient.
Beyond the University of Minnesota studies, we offer multicenter national trials including:
- Non-myeloablative allogeneic transplant for relapsed follicular non-Hodgkin lymphoma.
- Autologous transplant followed by maintenance with a novel antibody (SGN35) for high risk Hodgkin lymphoma.
- A new trial testing the antilymphoma potency of sirolimus to prevent relapse comparing sirolimus-based to standard regimens for GVHD prophylaxis and prevention of lymphoma recurrence.
- An NCI-funded study of Natural Killer (NK) cell therapy with rituximab, pentostatin and denileukin diffitox (Ontak) followed by infusion of haploidentical NK cells and IL2 for advanced or refractory lymphomas.
